Day: June 16, 2021

Lowest dose cohort complete and study positioned for dose escalation Company to present FLT190 data by year-end LONDON, June 16, 2021 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced dosing of the second patient in the ongoing Phase 1/2 MARVEL-1 clinical trial of FLT190, its liver-directed AAV gene therapy candidate for Fabry disease. “Dosing the second patient in the MARVEL-1 study is an important milestone for Freeline and evidence of progress in our Fabry program,” said Theresa Heggie, Chief Executive Officer of Freeline. “Easing of COVID-19 restrictions, together with geographic expansion of study...

Experienced Biopharma Executive with Track Record of Driving Commercial and Operational Success at Global CDMOs EXTON, Pa., June 16, 2021 (GLOBE NEWSWIRE) — Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the appointment of Laura L. Parks, Ph.D., to the company’s board of directors. Dr. Parks is an experienced business leader with a track record of developing high performance, market-focused teams at a number of leading global biopharma, CDMO and food industry companies. Retired since 2017, her more than three decades of expertise spans global leadership team collaboration, profit and loss (P&L) accountability, team culture development,...

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) — Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, announced that Douglas Love, Esq., President & Chief Executive Officer, will present at the virtual Raymond James Human Health Innovation Conference on June 23rd, 2021 at 1:20 pm EDT. A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. About Annexon, Inc.Annexon is a clinical-stage biopharmaceutical company developing a pipeline...

CHATHAM, N.J., June 16, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the Raymond James Human Health Innovation Conference on June 23, 2021, at 8:00 a.m. ET. Investors interested in arranging a virtual meeting with the Company’s management during the conference should contact the Raymond James conference coordinator. A webcast of the presentation will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com. About Tonix Pharmaceuticals Holding Corp. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics...

Weight loss of 5.4% achieved at 6 weeks of treatment with 1.8 mg once weekly dose, surpassing the 2% pre-established treatment target Ascending multi-dose regimen well-tolerated without necessity for dose titration Trial continuing with 12-week data expected in Q3 2021 Company plans to file an additional IND and initiate an obesity program in 2021 Altimmune to host a conference call today at 8:30 a.m. ETGAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced results from a prespecified 6-week interim analysis of its ongoing 12-week, Phase 1, placebo-controlled, single and multiple ascending dose trial of ALT-801, an investigational GLP-1/glucagon dual receptor agonist, in healthy overweight and obese volunteers. The study is currently being...

Image 1Map of planned 3D IP survey boundary and IP line orientation with relation to historic Bunker Hill mine footprint and contiguous claims packageImage 2Idealized long section of historic Bunker Hill workings and estimated 2021 PEA resource boundarySam Ash, CEO and David Wiens, CFO to host Live Interactive Virtual Investor Event on Wednesday, June 16 @ 11:00am ET / 8:00am PT. Investors are invited to register for this event at: LINK TORONTO, June 16, 2021 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (the “Company”) (CSE: BNKR, OTC: BHLL) is pleased to announce the initiation of a ground geophysical survey over the previously un-tested southern extension of its claims package. The program, scheduled for Q3 2021, will be conducted as a high-resolution 3D IP (DCIP) survey method from Dias Geophysical...

HAMILTON, Bermuda, June 16, 2021 (GLOBE NEWSWIRE) — SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE: SPNT; OTCQX: SSPCF) today announced that the company’s CVRs (Contingent Value Rights) have qualified to trade on the OTCQX® Best Market. The newly trading CVRs were issued to investors of Sirius International Insurance Group upon the merger of the company with Third Point Reinsurance Ltd. who elected to receive the Share & CVR consideration in advance of the merger, and to any “Non-Electing Holder”, who did not make a timely election for all of his or her shares, and who was therefore entitled to receive the Share & CVR Consideration with respect to those shares. They began trading on OTCQX on June 10, under the symbol “SSPCF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for...

NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) — Vroom, Inc. (Nasdaq: VRM) (“Vroom”) today announced the pricing of its offering of $550,000,000 aggregate principal amount of 0.750% convertible senior notes due 2026 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $500,000,000 aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on June 18, 2021, subject to customary closing conditions. Vroom also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional $75,000,000 principal amount...

VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain, is pleased to announce that it has submitted an application to list on The Nasdaq Stock Market (“Nasdaq”). The Company has reserved the right to trade under the symbol “DRUG.” Commenting on the plans for the Nasdaq listing, Ian McDonald, Chief Executive Officer of Bright Minds, said, “We believe that this is an ideal time for Bright Minds to announce its plans to move to a leading national stock exchange. Serotonergic therapeutics have gained considerable traction and are on the cusp of an exciting revolution in medicine. BMB is already moving to the...

STEINHAUSEN, Switzerland, June 16, 2021 (GLOBE NEWSWIRE) — Transocean Ltd. (NYSE: RIG) announced today the Transocean Barents was awarded a two-well contract in Norway with commencement expected in February 2022. The contract award is approximately 200 days in duration and adds an estimated $60 million in firm contract backlog. Additionally, the Transocean Norge was awarded a four-well contract plus five one-well options in Norway with commencement expected in March 2022. The contract award is approximately 200 days in duration and adds an estimated $56 million in firm contract backlog. About Transocean Transocean is a leading international provider of offshore contract drilling services for oil and gas wells. Transocean specializes in technically demanding sectors of the global offshore drilling business with a particular focus...